Loading...
•
Sep 30, 2024
Nektar Q3 2024 Earnings Report
Nektar reported financial results for the third quarter ended September 30, 2024.
Key Takeaways
Nektar Therapeutics reported third quarter 2024 financial results with revenue of $24.1 million and a net loss of $37.1 million, or $0.18 per share. The company's cash and investments in marketable securities were $249.0 million as of September 30, 2024, expected to support operations into the fourth quarter of 2026.
Advanced I&I pipeline, including Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata.
Rapid enrollment in the 400-patient atopic dermatitis study for rezpegaldesleukin, with topline data expected in the first half of 2025.
Phase 2 study in alopecia areata is also enrolling nicely with topline data expected in the second half of 2025.
Focused on advancing earlier stage TNFR2 antibody and bispecific programs, NKTR-0165 and NKTR-0166, with at least one of these slated to enter the clinic next year.
Forward Guidance
Nektar’s cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...